- In August 2021, Arena Pharmaceuticals formed a partnership with Second Genome, a biotechnology company, to identify gastrointestinal biomarkers. Second Genome will utilize its sg-4-sight research engine alongside Arena's Cultivate clinical trial to discover microbiome biomarkers. This collaboration aims to improve patient stratification and optimize potential treatments for gastrointestinal conditions, enhancing therapeutic precision
- In March 2021, Janssen Research and Development, LLC initiated a Phase III clinical trial to evaluate the safety of ustekinumab. The study is focused on assessing the treatment's effectiveness for pediatric patients suffering from moderate to severe Crohn's disease. This trial aims to provide valuable data to support ustekinumab's use in younger populations with this challenging condition
